Literature DB >> 7297017

Measurement of partial agonist activity of pindolol.

S G Carruthers, Y Twum-Barima.   

Abstract

The partial agonist activity of pindolol was assessed by examining the action of cumulative doses on the heart rate of resting, standing, and exercising healthy men and by studying the interaction of pindolol with metoprolol, a beta blocker devoid of partial agonist activity. Pindolol did not affect resting or standing heart rates (RHR, SHR) but reduced the heart rate after vigorous exercise by approximately 25%. The flatter dose-response curve of pindolol for exercise heart rate (EHR) has been reported from practolol and oxprenolol, which also exert partial agonist activity. After extremely large doses of pindolol there was no evidence of enhancement of agonist activity on RHR, nor was there any evidence of dominance of agonist activity over antagonist activity on EHR. Metoprolol did not alter RHR but reduced SHR by approximately 20% and EHR by approximately 31%. The effects of pindolol on SHRs and EHRs were not enhanced by metoprolol, even though the drug itself induced greater reductions of both. The reduction of SHR by metoprolol was reversed by pindolol. Pindolol appears to have greater affinity than metoprolol for atrial beta adrenoceptors in man.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7297017     DOI: 10.1038/clpt.1981.207

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

2.  Exercise haemodynamic effects of beta-blockade and intrinsic sympathomimetic activity.

Authors:  P A Ades; E E Wolfel; W R Hiatt; C Fee; R Rolfs; H L Brammell; L D Horwitz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant?

Authors:  D G McDevitt
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

4.  Cardiac effects of beta-adrenoceptor blockade with intrinsic sympathomimetic activity during submaximal exercise.

Authors:  P A Ades
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

5.  Cardiac dose-response relationships of oral and intravenous pindolol.

Authors:  S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Stereoselective renal clearance of pindolol in humans.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

7.  Comparison of the effect of pindolol and propranolol on heart rate after acute and chronic administration.

Authors:  M B Finch; P C O'Connor; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

8.  The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.

Authors:  T H Pringle; A J McNeill; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

9.  Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.

Authors:  T H Pringle; P C O'Connor; A J McNeill; M B Finch; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

10.  Contrasts between pindolol and propranolol concentration-response relationships.

Authors:  S G Carruthers; W L Pacha; W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.